Search
News & Events
The Kids Research Institute Australia Cancer Centre Researcher wins Cancer Council WA FellowshipCancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.
News & Events
“Natural killer” donor cells fighting kids leukaemiaNew research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.
News & Events
WA Child Research Fund grants boost research for premmies, kids with cancer and rare diseasesThe Kids Research Institute Australia researchers have been awarded 12 of 16 grants under the latest round of funding from the WA Child Research Fund
Research
SNAIL trail in myeloid malignanciesTranscription factors known to induce the epithelial-to-mesenchymal transition (EMT) (such as ZEB1/2 [zinc finger E-box binding homeobox 1/2], SNAI1/2/3, and TWIST1/2) have been undoubtedly implicated in tumorigenesis, cancer progression, metastasis, and chemoresistance in solid tumors; however, their role in normal and malignant hematopoiesis has been underappreciated for many years.
Research
Exposure to diagnostic radiological procedures and the risk of childhood acute lymphoblastic leukemiaDiagnostic irradiation of the mother during pregnancy increases the risk of childhood acute lymphoblastic leukemia
Research
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal diseaseInvasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.
Associate Professor Lesterhuis said the gel, developed with the help of chemists at The University of Western Australia, could revolutionise the way solid tumours were treated.
News & Events
WA-based cancer pharmaceutical start-up secures CUREator fundingResearchers dedicated to developing the first cancer immunotherapy tablet have been boosted by a $374,000 CUREator top-up funding grant.
Research
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialThere is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers.
Research
Directing the future breakthroughs in immunotherapy: The importance of a holistic approach to the tumour microenvironmentImmunotherapy has revolutionised the treatment of cancers by exploiting the immune system to eliminate tumour cells. Despite the impressive response in a proportion of patients, clinical benefit has been limited thus far.